Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease
Year: 2014
Type: article
Abstract: Health-care stakeholders increasingly recognize that the scientific and economic challenges associated with Alzheimer's disease (AD) are simply too great for individual stakeholder groups to address solely from within their own silos. In the necessary spirit of collaboration, we present in this perspective a set of multicountry multistakeholder recommendations to improve the organization of existing AD and dementia care and the development of new treatments. In brief, the five recommendations are (1) health-care systems must make choices regarding the patient populations to be diagnosed and treated, (2) health-care systems should use an evidence-based standard of care, (3) increased collaboration between public and private institutions is needed to enhance research, (4) reimbursement end points need to be agreed on and validated, and (5) innovative business models should be used to spur the introduction of new medicines.
Source: Alzheimer s & Dementia
Authors: Patrick Bradley, Ron Akehurst, Clive Ballard, Sube Banerjee, Kaj Blennow, Jennifer Bremner, Karl Broich, Jeffrey Cummings, Karen Dening, Bruno Dubois, Wiebke Klipper, Chris Leibman, Valentina Mantua, José Luis Molinuevo, Susan Morgan, Luisa A.A. Muscolo, François Nicolas, Luca Pani, Louise Robinson, Paolo Siviero, Julius van Dam, Jan VanEmelen, Anders Wimo, Marc Wortmann, Lindee Goh
Institutions: University of Sheffield, King's College London, Brighton and Sussex Medical School, University of Sussex, University of Gothenburg, European Health Management Association, Federal Institute for Drugs and Medical Devices, Cleveland Clinic, Lou Ruvo Brain Institute, Dementia UK, Pitié-Salpêtrière Hospital, Université Pierre-et-Marie-Curie, Biogen (United States), Gemeinsamer Bundesausschuss, Janssen Alzheimer Immunotherapy Research & Development (United States), Italian Medicines Agency, Pasqual Maragall Foundation, Hospital Clínic de Barcelona, Medicines and Healthcare products Regulatory Agency, Sanofi (France), Newcastle University, Karolinska Institutet, Alzheimer Disease International
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
OpenAlex ID: W2166139130